Abstract Details
|
Activity Number:
|
226
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Monday, August 5, 2013 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Biometrics Section
|
| Abstract - #307973 |
|
Title:
|
Implementing Adaptive Dose-Finding Designs in Oncology Clinical Trials
|
|
Author(s):
|
Bo Huang*+ and Paul Bycott and Enayet Talukder
|
|
Companies:
|
Pfizer Inc. and Pfizer Inc. and Pfizer Inc.
|
|
Keywords:
|
Dose Finding ;
Phase I ;
Adaptive Design ;
Oncology ;
MTD
|
|
Abstract:
|
The main objective in phase I oncology trials is to identify a maximum tolerated dose for subsequent studies. Over the past two decades, extensive research has been conducted by statisticians and clinical researchers to create innovative dose finding designs that perform better than the standard 3+3 design, which often exhibits undesirable statistical and operational properties. However, clinical implementation and practical usage have been limited. This article provides some perspectives on implementing adaptive dose finding designs in oncology phase I trials. A case study is provided to illustrate why, how and when novel statistical methodologies are adopted. Operational considerations on how to effectively conduct such trials are discussed.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.